Product Description
Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR- _/4-1BB lentiviral vector
Mechanisms of Action: CAR-T, CD19
Novel Mechanism: No
Modality: Autologous CAR-T
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shenzhen BinDeBio
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, B-Cell|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia|B-Cell Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2017ZDYFY-BinD19 | P2 |
Unknown status |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, B-Cell|B-Cell Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia |
2021-05-30 |
41% |
2023-02-03 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| 2017FDEK-BinD19 | P2 |
Unknown status |
Acute Lymphoid Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|B-Cell Leukemia|Lymphoma, B-Cell |
2021-05-30 |
21% |
2023-02-03 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
07/24/2019 |
News Article |
T-Cell Immunotherapies Market, 2019-2030 |